Ipca Laboratories Ltd
IPCALAB
Company Profile
Business description
Ipca Laboratories Ltd is a pharmaceutical company. The company's principal activity is the Development, Manufacturing, and Marketing of Pharmaceuticals Products. The company's API products include Atenolol (anti-hypertensive), Chloroquine Phosphate (anti-malarial), Chlorthalidone (diuretic), Furosemide (diuretic), Hydroxychloroquine Sulphate (DMARD), Losartan. The company has only one reportable primary business segment, pharmaceuticals.
Contact
No. 48, 123 AB, 125 & 126 Kandivli Industrial Estate
Kandivli (West)
MumbaiMH400067
INDT: +91 2262105000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2027
Employees
23,236
Stocks News & Analysis
stocks
Margins have bottomed for ASX listed consumer goods company
Impact of tariffs have been priced in.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,016.40 | 33.30 | -0.37% |
| CAC 40 | 8,400.11 | 21.03 | -0.25% |
| DAX 40 | 25,139.69 | 153.87 | 0.62% |
| Dow JONES (US) | 51,712.71 | 148.01 | 0.29% |
| FTSE 100 | 10,437.85 | 74.58 | 0.72% |
| HKSE | 23,767.87 | 0.65 | -0.00% |
| NASDAQ | 26,166.60 | 351.33 | -1.32% |
| Nikkei 225 | 71,690.37 | 663.59 | -0.92% |
| NZX 50 Index | 13,481.07 | 35.02 | 0.26% |
| S&P 500 | 7,472.79 | 27.79 | -0.37% |
| S&P/ASX 200 | 8,811.20 | 23.90 | -0.27% |
| SSE Composite Index | 4,166.47 | 3.38 | 0.08% |